Drug intelligence / Profile preview

SJN-311

Development stage: Preclinical
Lead developer: Samjin Pharmaceutical
Modality: Small Molecules

Overview

SJN-311 (also known as SJN311) is a preclinical-stage small molecule immuno-oncology candidate being developed by Samjin Pharmaceutical. It is designed to target immune-resistant solid tumors. The drug is part of Samjin's strategic expansion into high-value specialty care areas, including oncology and rare diseases, and is currently undergoing early-stage discovery and preclinical evaluation.

Beyond the preview

Go deeper on SJN-311.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SJN-311.

Explore the full profile